Amgen Lays Out Plans For Rare Disease Portfolio Growth

Ex-US Push, Subcutaneous Dosing For Tepezza

 
• By Mandy Jackson
  
Male red plastic toy businessman silhouette wooden crowd figure background closeup
Rare disease is one of four pillars for Amgen besides general medicine, inflammation and oncology • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Rare Diseases

More from Scrip